The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer

摘要

Axillary lymph node dissection after neoadjuvant chemotherapy still remains a standard treatment of patients with breast cancer with LN metastases before neoadjuvant chemotherapy. Our results showed that 3 or more residual lymph node metastases after NAC were rare in patients with LN metastases before neoadjuvant chemotherapy with estrogen receptor-negative/human epidermal growth factor receptor 2-positive or estrogen receptor-negative/human epidermal growth factor receptor 2-negative tumors who were assessed as clinically lymph node-negative after neoadjuvant chemotherapy by ultrasonography. It indicated that no complete axillary lymph node dissection might be needed for these populations.